Clinical Trial Update: Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial protocol evaluating Vedisertib (RC48/ADC) in combination with Toripalimab for bladder-preserving treatment in muscle-invasive bladder cancer; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• Toripalimab (Toripalimab)
• Vedisertib (RC48/ADC)

Snippet

Sponsor: Qilu Hospital of Shandong University | Conditions: Muscle Invasive Bladder Cancer (MIBC) | Phase 2 | Status: NOT_YET_RECRUITING